- Home
- IBRX vs HTFL Comparison
IBRX vs HTFL Comparison
Compare IBRX & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IBRX | HTFL |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.4B |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | IBRX | HTFL |
|---|---|---|
| Price | $2.38 | $27.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $9.71 | ★ $39.50 |
| AVG Volume (30 Days) | ★ 11.5M | 617.5K |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $82,555,000.00 | ★ $161,881,000.00 |
| Revenue This Year | $667.18 | $40.42 |
| Revenue Next Year | $88.32 | $22.27 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1025.95 | 85.70 |
| 52 Week Low | $1.83 | $25.75 |
| 52 Week High | $4.27 | $41.22 |
Technical Indicators
Market Signals| Indicator | IBRX | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 56.50 | N/A |
| Support Level | $2.17 | N/A |
| Resistance Level | $2.40 | N/A |
| Average True Range (ATR) | 0.15 | 0.00 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 72.22 | 0.00 |
Price Performance
Historical ComparisonAbout IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About HTFL Heartflow Inc.
HeartFlow Inc is a commercial-stage medical technology company that has pioneered the use of software and AI to deliver a non-invasive solution for diagnosing and managing coronary artery disease CAD. The company operates and manages its business as one reportable and operating segment, which is the business of non-invasive coronary artery disease detection solutions. Geographically, it operates in United States, United Kingdom, Japan, and Rest of Europe, of which it derives maximum revenue from United States.